<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346317</url>
  </required_header>
  <id_info>
    <org_study_id>No.5-20171111</org_study_id>
    <nct_id>NCT03346317</nct_id>
  </id_info>
  <brief_title>Comparing the Efficacy of Two Methods in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis</brief_title>
  <official_title>Randomized, Controlled Trial to Assess the Efficacy of Disposable Balloon Uterine Stent Combined With Estrogen or Dried Biological Amnion Graft for the Therapy of Uterine Adhesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Obstetrics and Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Obstetrics and Gynecology Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asherman's syndrome is characterized by the presence of intrauterine adhesions (IUA) as well
      as symptoms such as amenorrhea, hypomenorrhea, pelvic pain, and infertility. The gold
      standard for the treatment of intrauterine adhesions is hysteroscopic intrauterine adhesions.
      The recurrence of intrauterine adhesions is a major challenge in clinical practice. It has
      been reported that dried biological aminion graft was used to prevent adhesion after the
      operation of intrauterine adhesions. Estrogen is also used for postoperative prevention of
      intrauterine adhesions. Intrauterine balloon can reduce the recurrence of adhesions after
      operation. Does the combination of balloon with amniotic products or estrogen can improve
      clinical outcomes? Therefore, this study was conducted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel
      Assignment Masking: Double (participant and outcomes Assessor) Primary Purpose: Prevention
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">May 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adhesion information</measure>
    <time_frame>Within the first 3 months after surgery</time_frame>
    <description>Intrauterine adhesions under hysteroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Menstruation pattern</measure>
    <time_frame>Within the first 3 months after surgery</time_frame>
    <description>menstrual volume which was assessed by pictorial blood loss assessment chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of AFS score</measure>
    <time_frame>Within the first 3 months after surgery</time_frame>
    <description>The American Fertility Society ( AFS ) scoring system (1988 version). Scores of 1-4, 5-8, and 9-12 were mild, moderate, and severe adhesions, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Intrauterine Adhesion</condition>
  <arm_group>
    <arm_group_label>dried biological amnion graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>disposable balloon uterine stent</intervention_name>
    <description>The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.</description>
    <arm_group_label>dried biological amnion graft</arm_group_label>
    <arm_group_label>estrogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dried biological amnion graft</intervention_name>
    <description>Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane</description>
    <arm_group_label>dried biological amnion graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol valerate tablets+dydrogesterone tablets</intervention_name>
    <description>oral estradiol valerate tablets+dydrogesterone tablets</description>
    <arm_group_label>estrogen</arm_group_label>
    <other_name>Progynova+dydrogesterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 20-40 years；

          -  previously diagnostic hysteroscopy confirmed adhesion score &gt;5， according to the
             American Fertility Society （AFS）classification of IUA；

          -  complains of menstruation disorder and reproductive dysfunction；

          -  informed consent.

        Exclusion Criteria:

          -  premature menopause,

          -  presence of other intrauterine lesions (e.g. polyps, myoma, septa), and

          -  presence of severe intercurrent illness (e.g. systemic disease, coagulative disorders,
             severe kidney and liver diseases),

          -  adhesions limited to the lower uterine cavity or the cervical canal.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duan Hua, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Obstetrics and Gynecology Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhu Ru, MD</last_name>
    <phone>13966636438</phone>
    <email>zhuru19790202@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Sha, MD</last_name>
    <phone>15201556908</phone>
    <email>wangsha1020@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Obstetrics and Gynecology Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu Zhen</last_name>
      <phone>+8613718210767</phone>
      <email>fcyykyb@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asherman syndrome</keyword>
  <keyword>hysteroscopy</keyword>
  <keyword>Uterine stent</keyword>
  <keyword>Estrogen</keyword>
  <keyword>Amnion</keyword>
  <keyword>Hysteroscopic Adhesiolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

